New mesothelioma study focuses on personalized treatment

14 Mar 2018 by under Research/Treatment

587px Researcher looks through microscope 1 100x100 New mesothelioma study focuses on personalized treatmentThe Leicester Research program, a multidisciplinary research partnership between the University of Leicester and University Hospitals of Leicester NHS trust, received a donation of about $3.5 million from the British Lung Foundation to develop a groundbreaking new umbrella study on .

Called the Mesothelioma Stratified Therapy, or MisT, the study will focus on personalized medical treatment for patients with mesothelioma. The study aims to identify which patients are likely to get the greatest benefit from the therapies that are available. “Some patients’ mesothelioma are drug-sensitive, whilst others are resistant,” the organization said in a statement. “In recent years, it has become clear that in order to maximize the benefit of anticancer drugs, a one-size-fits-all approach is no longer applicable.”

The trial is accepting patients with mesothelioma who have been treated with chemotherapy unsuccessfully. Participants’ tumors will be categorized based on the presence of specific molecular biomarkers, and will receive up to four different treatments sequentially.

Researchers hope that by identifying information from the original biopsy, they can gain a greater understanding of why patients do or do not respond to specific treatments, and how best to treat them going forward. They also hope to gain an understanding as to what makes tumors resistant to specific treatments.

Mesothelioma is a rare and deadly disease that affects the tissue that lines the lungs, stomach, heart, and other organs. Malignant mesothelioma, which primarily affects the lungs, is the most common form. It is caused by exposure to , a fibrous mineral that decades ago was widely used in fire-resistant and insulating materials.


Comments are closed.